Research from Atrium Research, Atrium Research Corporation

Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis.

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>Sabio reported Q3/25 financial results that missed our expectations, with revenue coming in at $8.2M (-49% YoY), compared to our estimate of $11.2M.</li>
<li>Adjusted EBITDA was ($2.2M) vs. our expected $1.3M.</li>
<li>While the quarter was weak, management remains bullish on 2026, stating that its Q1 pipeline is up 60% YoY.</li>
</ul>


Sabio reported Q3/25 financial results that missed our expectations, with revenue coming in at $8.2M (-49% YoY), compared to our estimate of $11.2M.
Adjusted EBITDA was ($2.2M) vs. our expected $1.3M.
While the quarter was weak, management remains bullish on 2026, stating that its Q1 pipeline is up 60% YoY.


SBIO: Weak Q3 Financials; Still Eyeing 2026

Sabio Holdings

SBIO: Weak Q3 Financials; Still Eyeing 2026